Raised blood pressure remains the leading modifiable risk factor for cardiovascular disease and premature mortality worldwide, affecting an estimated 1·3 billion adults.1 Although most patients ...

MADRID, Spain—Baxdrostat (AstraZeneca), an investigational aldosterone synthase inhibitor, provides substantial reductions in blood pressure when added to background therapy in patients with ...

A new study from researchers at Brigham and Women’s Hospital suggests that a hormone called aldosterone may play a much larger role in high blood pressure than doctors previously believed. This ...

In a phase 2 trial, an investigational drug that inhibits aldosterone synthase significantly lowered albuminuria in patients with or without type 2 diabetes. PHILADELPHIA—A novel selective aldosterone ...

Aldosterone escape and non-ACE pathways for angiotensin II production may explain, at least in part, the continued high mortality rates in heart failure patients despite the advances made in ...

Mineralys' lorundrostat, a selective aldosterone synthase inhibitor, shows promise in treating resistant hypertension with fewer side effects compared to current MRAs. Upcoming catalysts include ...

Aldosterone was isolated from blood and urine, its adrenal origin elucidated, and its steroid structure identified nearly 50 years ago. Actions involving the reabsorption of sodium and the release of ...

Please provide your email address to receive an email when new articles are posted on . Once-daily lorundrostat, an aldosterone synthase inhibitor, significantly decreased automated office systolic BP ...

When the heart begins to fail, the body does everything in its power to fix the situation. But sometimes, those compensatory mechanisms ultimately do more harm than good. Such is the case with the ...